These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17853505)

  • 21. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating the pharmaceutical industry. Authors seem to have misunderstood pharmaceutical price regulation scheme.
    Read P
    BMJ; 1998 Jan; 316(7126):226; author reply 228. PubMed ID: 9468700
    [No Abstract]   [Full Text] [Related]  

  • 24. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value elements and methods of value-based pricing for drugs in Japan: a systematic review.
    Takami A; Kato M; Deguchi H; Igarashi A
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):749-759. PubMed ID: 37339436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK.
    Borrell JR
    Pharmacoeconomics; 1999 Mar; 15(3):291-303. PubMed ID: 10537436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.
    Godman B; Haycox A; Schwabe U; Joppi R; Garattini S
    Pharmacoeconomics; 2008; 26(2):91-8. PubMed ID: 18198930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Is the price of cancer drugs related to the cost of develo-pment and production or to the economic value of their clincal efficacy?].
    Russi A; Serena M; Palozzo AC
    Recenti Prog Med; 2016 Apr; 107(4):181-5. PubMed ID: 27093327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
    Ha SY; Kang DW; Jung HI; Lee EK; Park MH
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In practice: the NHS market in the United Kingdom. Health Policy Network of the National Health Service Consultant's Association and the National Health Service Support Federation.
    J Public Health Policy; 1995; 16(4):452-91. PubMed ID: 8907766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The drug price is right--or is it?
    Siva N
    Lancet; 2009 Apr; 373(9672):1326-7. PubMed ID: 19382291
    [No Abstract]   [Full Text] [Related]  

  • 35. Securing sustainable price levels of innovative anticancer drugs: How to move forward?
    Franzen N; Retèl V; van Harten W
    J Cancer Policy; 2021 Mar; 27():100266. PubMed ID: 35559942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Private versus social incentives for pharmaceutical innovation.
    González P; Macho-Stadler I; Pérez-Castrillo D
    J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health care reform: managed competition and beyond.
    Custer W
    EBRI Issue Brief; 1993 Mar; (135):1-33. PubMed ID: 10129612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Universal coverage and cost control: the United Kingdom National Health Service.
    Maynard A; Bloor K
    J Health Hum Serv Adm; 1998; 20(4):423-41. PubMed ID: 10338720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.